A new therapy for severe ischemic heart disease has been developed; therapeutic angiogenesis induced by the local implantation of autologous bone marrow cells (BMC). After confirming that no detrimental changes were induced by this treatment in a canine heart model, a clinical trial was commenced in 1999. Thus far, 5 patients have been given this new treatment concomitant with coronary artery bypass grafting and all have been followed up for at least 1 year. Autologous BMC were implanted into the ungraftable area and postoperative cardiac scintigraphy showed specific improvement in coronary perfusion in 3 of the 5 patients. Postoperative chest radiography, electrocardiography, echocardiography and blood tests did not reveal any detrimental changes. In conclusion, this new therapy appears to be safe and could provide a treatment option for patients with otherwise untreatable ischemic heart disease.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Hamano, K., Nishida, M., Hirata, K., Mikamo, A., Li, T. S., Harada, M., … Esato, K. (2001). Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease - Clinical trial and preliminary results. Japanese Circulation Journal, 65(9), 845–847. https://doi.org/10.1253/jcj.65.845